MA46842A - Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 - Google Patents
Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8Info
- Publication number
- MA46842A MA46842A MA046842A MA46842A MA46842A MA 46842 A MA46842 A MA 46842A MA 046842 A MA046842 A MA 046842A MA 46842 A MA46842 A MA 46842A MA 46842 A MA46842 A MA 46842A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- treating obesity
- angptl8 antibodies
- angptl8
- antibodies
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423639P | 2016-11-17 | 2016-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46842A true MA46842A (fr) | 2019-09-25 |
Family
ID=60655071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046842A MA46842A (fr) | 2016-11-17 | 2017-11-16 | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10442856B2 (enExample) |
| EP (1) | EP3541839A1 (enExample) |
| JP (1) | JP7133551B2 (enExample) |
| KR (1) | KR20190078650A (enExample) |
| CN (1) | CN110036029A (enExample) |
| AU (1) | AU2017363143B2 (enExample) |
| CA (1) | CA3044249A1 (enExample) |
| EA (1) | EA201991203A1 (enExample) |
| IL (1) | IL266564A (enExample) |
| MA (1) | MA46842A (enExample) |
| MX (1) | MX382035B (enExample) |
| WO (1) | WO2018094112A1 (enExample) |
| ZA (1) | ZA201902608B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| US10774139B2 (en) | 2017-11-10 | 2020-09-15 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| EP4004051A4 (en) | 2019-07-19 | 2023-08-23 | Oncoresponse, Inc. | IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN111690058B (zh) * | 2020-03-30 | 2021-02-05 | 三优生物医药(上海)有限公司 | 针对冠状病毒的具有中和活性的抗体及其用途 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US20020132252A1 (en) | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7393663B2 (en) | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| NZ523206A (en) | 1999-08-31 | 2004-12-24 | Genentech Inc | Antibodies that bind to tumor gene sequences |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
| JP2010529954A (ja) | 2007-05-22 | 2010-09-02 | ノバルティス アーゲー | Ｆｇｆ２１関連障害を処置、診断および検出する方法 |
| EP2679234A3 (en) | 2009-12-02 | 2014-04-23 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MX386832B (es) | 2016-04-08 | 2025-03-19 | Regeneron Pharma | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
-
2017
- 2017-11-16 CN CN201780070860.4A patent/CN110036029A/zh active Pending
- 2017-11-16 KR KR1020197017245A patent/KR20190078650A/ko not_active Ceased
- 2017-11-16 EA EA201991203A patent/EA201991203A1/ru unknown
- 2017-11-16 JP JP2019526287A patent/JP7133551B2/ja active Active
- 2017-11-16 AU AU2017363143A patent/AU2017363143B2/en not_active Expired - Fee Related
- 2017-11-16 MA MA046842A patent/MA46842A/fr unknown
- 2017-11-16 EP EP17812128.1A patent/EP3541839A1/en active Pending
- 2017-11-16 WO PCT/US2017/062103 patent/WO2018094112A1/en not_active Ceased
- 2017-11-16 MX MX2019005651A patent/MX382035B/es unknown
- 2017-11-16 CA CA3044249A patent/CA3044249A1/en not_active Abandoned
- 2017-11-17 US US15/815,881 patent/US10442856B2/en active Active
-
2019
- 2019-04-24 ZA ZA2019/02608A patent/ZA201902608B/en unknown
- 2019-05-12 IL IL266564A patent/IL266564A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017363143B2 (en) | 2022-07-28 |
| WO2018094112A1 (en) | 2018-05-24 |
| JP7133551B2 (ja) | 2022-09-08 |
| CN110036029A (zh) | 2019-07-19 |
| EP3541839A1 (en) | 2019-09-25 |
| KR20190078650A (ko) | 2019-07-04 |
| ZA201902608B (en) | 2020-07-29 |
| CA3044249A1 (en) | 2018-05-24 |
| US10442856B2 (en) | 2019-10-15 |
| MX382035B (es) | 2025-03-13 |
| US20180134781A1 (en) | 2018-05-17 |
| JP2020500852A (ja) | 2020-01-16 |
| MX2019005651A (es) | 2019-11-12 |
| EA201991203A1 (ru) | 2019-10-31 |
| IL266564A (en) | 2019-07-31 |
| AU2017363143A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47206A (fr) | Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 | |
| MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 | |
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| EP3454945A4 (en) | ASH11 INHIBITORS AND METHOD FOR TREATING THEM | |
| EP3723803A4 (en) | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES | |
| LT3988656T (lt) | Su nukleosoma sąveikaujančių baltymų domenų panaudojimas tikslinės genomo modifikacijos pagerinimui | |
| EP3478286A4 (en) | METHOD FOR TREATING OVARY CANCER | |
| EP3752180A4 (en) | METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES | |
| MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
| EP3334765A4 (en) | CHIMERIC ANTIGEN RECEPTORS BASED ON INDIVIDUAL DOMAIN ANTIBODIES AND METHOD FOR USE THEREOF | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| EP3389725A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| EP3573658A4 (en) | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS | |
| EP3383917A4 (en) | Novel anti-claudin antibodies and methods of use | |
| EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
| EP3442996A4 (en) | TREATMENT PROCEDURE WITH CHLOROTOXIN CONJUGATES | |
| EP3773632A4 (en) | Methods of treating egfrviii expressing glioblastomas | |
| EP3313395A4 (en) | METHOD FOR THE TREATMENT OF INFLAMMATION THROUGH NATURAL CONNECTIONS AND / OR NUTRITION | |
| EP3405191A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS | |
| EP3458079A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ACNE | |
| MA45997A (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
| EP3007722A4 (en) | METHOD FOR THE TREATMENT OF HYPOTONIA | |
| EP3402883A4 (en) | COMPOSITIONS AND METHODS FOR THE SEQUENCING OF NUCLEIC ACIDS | |
| EP3373937A4 (en) | ANTI-CD22 ANTIBODY MAYTANSIN CONJUGATES AND METHOD OF USE THEREOF | |
| EP3522865A4 (en) | METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE |